TC Biopharm (Holdings) Plc Stock price

Equities

TCBP

US87807D4007

Biotechnology & Medical Research

End-of-day quote Nasdaq 07:00:00 2024-03-25 pm EDT 5-day change 1st Jan Change
1.42 USD -1.39% Intraday chart for TC Biopharm (Holdings) Plc -12.35% -55.21%
Sales 2021 1.98M 2.5M Sales 2022 3.84M 4.85M Capitalization 3.02M 3.82M
Net income 2021 -13M -16.41M Net income 2022 -1M -1.26M EV / Sales 2021 * -
Net Debt 2021 15.07M 19.02M Net cash position 2022 2.01M 2.54M EV / Sales 2022 0.26 x
P/E ratio 2021 *
-
P/E ratio 2022
-1.57 x
Employees 60
Yield 2021 *
-
Yield 2022
-
Free-Float 74.24%
More Fundamentals * Assessed data
Dynamic Chart
European Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Slightly Higher in Friday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Ease Wednesday MT
European Equities Traded in the US as American Depositary Receipts Flat in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Start Week Slightly Lower in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Friday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading MT
More news
1 day-1.39%
1 week-12.35%
Current month+12.70%
1 month+5.58%
3 months-51.03%
6 months-83.08%
Current year-55.21%
More quotes
1 week
1.30
Extreme 1.3
1.59
1 month
0.87
Extreme 0.8701
3.17
Current year
0.85
Extreme 0.8501
3.35
1 year
0.85
Extreme 0.8501
44.00
3 years
0.85
Extreme 0.8501
3 500.00
5 years
0.85
Extreme 0.8501
3 500.00
10 years
0.85
Extreme 0.8501
3 500.00
More quotes
Managers TitleAgeSince
Founder 64 12-12-31
Chief Executive Officer 44 21-05-31
Director of Finance/CFO 72 14-12-31
Members of the board TitleAgeSince
Director/Board Member 70 22-02-21
Director of Finance/CFO 72 14-12-31
Chairman 72 22-02-21
More insiders
Date Price Change Volume
24-03-28 1.31 -8.39% 413,934
24-03-27 1.43 +0.70% 381,690
24-03-26 1.42 -1.39% 191,016
24-03-25 1.44 -5.26% 226,139
24-03-22 1.52 -6.17% 231,793

End-of-day quote Nasdaq, March 25, 2024

More quotes
TC BioPharm Limited is a clinical-stage biopharmaceutical company. The Company is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma-delta T cell therapies for the treatment of infectious disease. The Company's platform technology allows the Company to design specific therapies to treat a range of cancers and infectious diseases with off-the-shelf allogeneic gamma-delta T cell (GDT) products. The Company's pipeline includes OmnImmune and CAR-T programs. OmnImmune is an unmodified allogeneic gamma-delta T cell product being used for the treatment of acute myeloid leukemia (AML). The Company has completed a Phase II clinical trial. Its CAR-T programs include in-house and partner programs at the pre-clinical-stage focused on developing CAR modified allogeneic gamma delta T-cell products targeting solid and hematological indications.
More about the company
  1. Stock
  2. Equities
  3. Stock TC Biopharm (Holdings) Plc - Nasdaq